Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy

Jeffrey J. Raizer*, Mark G. Malkin, Martin Kleber, Lauren E. Abrey

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences